Clinical Study of mRNA Vaccine in Patients With Advanced Malignant Solid Tumors

Summary

This study is an open, single arm, dose increasing study to evaluate the safety and efficacy of the combination of mRNA personalized tumor vaccine encoding neoantigen (hereinafter referred to as tumor vaccine) and Sintilimab injection (hereinafter referred to as Sintilimab) in the treatment of advanced malignant solid tumors.

Timeline

Start

2023-07-20

Primary completion

2025-12-12

Completion

2026-03-20

Drugs

Indications